Evidence map›Paper›PMID 36278187›Full record

ArticleFrontiers in pharmacology2022

Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase Ⅲ trial.

Ximei Wang, Xiaolei Hu, Nianyue Bai, Lie Li, Min Zhang, Zhigang Cheng, Qulian Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam.European journal of drug metabolism and pharmacokinetics · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ximei WangDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaolei HuNational Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nianyue BaiDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lie LiYichang Humanwell Pharmaceutical Co., Ltd., Yichang, Hubei, China.
Min ZhangDepartment of Clinical Research Center, Yichang Humanwell Pharmaceutical Co., Ltd., Yichang, Hubei, China.
Zhigang ChengDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qulian GuoDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiangya Hospital Central South University · CNHumanwell Healthcare Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverseeventspropofolremimazolam besylatesedation

Identifiers

PMID36278187
PMCPMC9579314
OpenAlexW4301393719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.